• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Enlivex Therapeutics and Unusual Machines Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

    3/22/24 10:50:00 AM ET
    $ENLV
    $UMAC
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Radio And Television Broadcasting And Communications Equipment
    Technology
    Get the next $ENLV alert in real time by email

    ORLANDO, FL / ACCESSWIRE / March 22, 2024 / RedChip Companies will air interviews with Enlivex Therapeutics Ltd. (NASDAQ:ENLV) and Unusual Machines Inc. (NYSE:UMAC) on the RedChip Small Stocks, Big Money™ show, a sponsored program on Bloomberg TV, this Saturday, March 23, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.

    Access the interviews in their entirety at:

    • Enlivex Therapeutics: https://www.redchip.com/assets/access/enlv_access
    • Unusual Machines: https://www.redchip.com/assets/access/umac_access

    In an exclusive interview, Oren Hershkovitz, CEO of Enlivex Therapeutics, appears on the RedChip Small Stocks Big Money™ show on Bloomberg TV to provide a corporate update. Enlivex presents a compelling investment opportunity in the biopharmaceutical sector with its innovative approach to treating life-threatening and debilitating conditions through macrophage reprogramming. The company's leading product, Allocetra™, is a groundbreaking, off-the-shelf cost-effective cell therapy platform designed to reset the body's immune cells (macrophages) to their optimal functioning state. This technology addresses a critical need for rebalancing the immune system, offering potential treatments for a range of inflammatory and autoimmune diseases with high unmet medical needs. With macrophages playing a vital role as the body's first line of defense, Enlivex's focus on converting these cells from a "disease setting" back to their "resolution settings" opens the door to addressing complex conditions like sepsis and osteoarthritis, tapping into multi-billion-dollar markets.

    Allan Evans, CEO of Unusual Machines, appears on the RedChip Small Stocks, Big Money™ show on Bloomberg TV to provide a corporate update. Unusual Machines is gathering great teams, revenue generating customers, valuable IP, and high-quality brands, growing both organically and through strategic acquisitions within the highly fragmented drone industry. The Company is focused on investing in the development or acquisition of FPV products and services that serve a broad set of industries including consumer, public safety, and drone delivery. The Company's Fat Shark and Rotor Riot subsidiaries are setting the standard for FPV immersive experiences and are expected to continue to corner the consumer FPV market as Unusual Machines expands into new enterprise verticals over the next 24 months. As Unusual Machines capitalizes on the wealth of opportunities in the rapidly evolving drone market it is well positioned for long-term success.

    About Enlivex Therapeutics

    Enlivex is a clinical-stage macrophage reprogramming immunotherapy company developing AllocetraTM, a universal, off-the-shelf cell therapy designed to reprogram macrophages into their homeostatic state. Resetting non-homeostatic macrophages into their homeostatic state is critical for immune system rebalancing and resolution of life-threatening conditions. For more information, visit http://www.enlivex.com.

    About Unusual Machines

    Unusual Machines manufactures and sells drone components and drones across a diversified brand portfolio, which includes Fat Shark, the leader in FPV (first-person view) ultra-low latency video goggles for drone pilots. The Company also retails small, acrobatic FPV drones and equipment directly to consumers through the curated Rotor Riot e-commerce store. With a changing regulatory environment, Unusual Machines seeks to be a dominant Tier-1 parts supplier to the fast-growing multi-billion-dollar US drone industry. According to Fact.MR, the global drone accessories market is currently valued at $17.5 billion and is set to top $115 billion by 2032.

    For more information visit Unusual Machines at https://www.unusualmachines.com/.

    About RedChip Companies

    RedChip Companies, an Inc. 5000 company, is an international investor relations, media, and research firm focused on microcap and small-cap companies. For 32 years, RedChip has delivered concrete, measurable results for its clients. Our newsletter, Small Stocks, Big Money™, is delivered online weekly to 60,000 investors. RedChip has developed the most comprehensive service platform in the industry for microcap and small-cap companies. These services include the following: a worldwide distribution network for its stock research; retail and institutional roadshows in major U.S. cities; outbound marketing to stock brokers, RIAs, institutions, and family offices; a digital media investor relations platform that has generated millions of unique investor views; investor webinars and group calls; a television show, Small Stocks, Big Money™, which airs weekly on Bloomberg US; TV commercials in local and national markets; corporate and product videos; website design; and traditional investor relation services, which include press release writing, development of investor presentations, quarterly conference call script writing, strategic consulting, capital raising, and more.

    To learn more about RedChip's products and services, please visit:

    https://www.redchip.com/corporate/investor_relations

    "Discovering Tomorrow's Blue Chips Today"™

    Follow RedChip on LinkedIn: https://www.linkedin.com/company/redchip/
    Follow RedChip on Facebook: https://www.facebook.com/RedChipCompanies
    Follow RedChip on Instagram: https://www.instagram.com/redchipcompanies/
    Follow RedChip on Twitter: https://twitter.com/RedChip
    Follow RedChip on YouTube: https://www.youtube.com/@redchip
    Follow RedChip on Rumble: https://rumble.com/c/c-3068340
    Subscribe to our Mailing List: https://www.redchip.com/newsletter/latest

    Contact:

    Dave Gentry
    RedChip Companies Inc.
    1-800-RED-CHIP (733-2447)
    Or 407-491-4498
    [email protected]

    SOURCE: RedChip Companies Inc.



    View the original press release on accesswire.com

    Get the next $ENLV alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ENLV
    $UMAC

    CompanyDatePrice TargetRatingAnalyst
    Unusual Machines Inc.
    $UMAC
    12/18/2024$18.00Buy
    Maxim Group
    More analyst ratings

    $ENLV
    $UMAC
    SEC Filings

    View All

    SEC Form 6-K filed by Enlivex Therapeutics Ltd.

    6-K - Enlivex Therapeutics Ltd. (0001596812) (Filer)

    8/18/25 8:00:23 AM ET
    $ENLV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by Enlivex Therapeutics Ltd.

    6-K - Enlivex Therapeutics Ltd. (0001596812) (Filer)

    8/18/25 7:47:26 AM ET
    $ENLV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-Q filed by Unusual Machines Inc.

    10-Q - Unusual Machines, Inc. (0001956955) (Filer)

    8/14/25 4:04:01 PM ET
    $UMAC
    Radio And Television Broadcasting And Communications Equipment
    Technology

    $ENLV
    $UMAC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Financial Officer Hoff Brian Joseph was granted 75,000 shares, increasing direct ownership by 22% to 416,725 units (SEC Form 4)

    4 - Unusual Machines, Inc. (0001956955) (Issuer)

    7/2/25 7:39:46 PM ET
    $UMAC
    Radio And Television Broadcasting And Communications Equipment
    Technology

    Chief Executive Officer Evans Allan Thomas was granted 175,000 shares (SEC Form 4)

    4 - Unusual Machines, Inc. (0001956955) (Issuer)

    7/2/25 7:38:11 PM ET
    $UMAC
    Radio And Television Broadcasting And Communications Equipment
    Technology

    Chief Operating Officer Camden Andrew Ross was granted 75,000 shares, increasing direct ownership by 47% to 233,500 units (SEC Form 4)

    4 - Unusual Machines, Inc. (0001956955) (Issuer)

    7/2/25 7:36:43 PM ET
    $UMAC
    Radio And Television Broadcasting And Communications Equipment
    Technology

    $ENLV
    $UMAC
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Enlivex Announces Positive Topline Data From Multi-Country, Randomized, Controlled, Phase I/II Trial Evaluating Allocetra in Patients With Moderate-To-Severe Knee Osteoarthritis

    ENX-CL-05-001 Trial: 3-months topline data -   In the overall modified intention-to-treat (mITT) population, improvements across all efficacy and secondary endpoints, including 24% reduction in knee pain and 26% improvement in knee function, were observed in the AllocetraTM treatment arm vs placebo; moreover, 72% reduction in knee pain and 95% improvement in knee function were observed for age-related primary osteoarthritis patients compared with placebo – a substantial, clinically meaningful and statistically significant effect in commonly used Phase III primary endpoints for knee osteoarthritis clinical trials. -   Favorable safety profile – No severe adverse events; limited, typically m

    8/18/25 7:45:00 AM ET
    $ENLV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Enlivex to Present 3-Month Topline Data from Phase IIa Moderate/Severe Knee Osteoarthritis Trial on August 18 Webinar

    Webinar to Review Results from Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study Evaluating Allocetra™ in Patients with Moderate to Severe Knee Osteoarthritis Nes-Ziona, Israel, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (NASDAQ:ENLV, the "Company")), a clinical-stage macrophage reprogramming immunotherapy company, today announced it will host a webinar on Monday, August 18, 2025, at 8:00 AM Eastern Time to present and discuss 3-month topline results from the Phase IIa stage of its Phase I/IIa ENX-CL-05-001 trial, a double-blind, randomized, placebo-controlled multi-centered study.  The webinar will feature a detailed analysis of 3-month topline data from

    8/14/25 8:30:00 AM ET
    $ENLV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Enlivex Reaffirms August 18, 2025 As Target Date For Announcement of Phase II Topline Data

    Nes-Ziona, Israel, July 28, 2025 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (NASDAQ:ENLV, the "Company")), a clinical-stage macrophage reprogramming immunotherapy company, today announced that all 134 patients in its Phase II stage of its randomized, controlled, blinded Phase I/II trial of Allocetra™ in patients with moderate to severe knee osteoarthritis, have completed a follow-up period of at least three months, the trial's primary timepoint for measurement of key endpoints. The data are being analyzed and audited, with a target date of August 18, 2025 for the public release of audited topline results for three-month key endpoints, including safety and change from baseline in knee p

    7/28/25 8:30:00 AM ET
    $ENLV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ENLV
    $UMAC
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Lowry Robert Paul bought $50,000 worth of shares (32,895 units at $1.52), increasing direct ownership by 81% to 73,502 units (SEC Form 4)

    4 - Unusual Machines, Inc. (0001956955) (Issuer)

    10/31/24 4:02:18 PM ET
    $UMAC
    Radio And Television Broadcasting And Communications Equipment
    Technology

    Chief Executive Officer Evans Allan Thomas bought $99,999 worth of shares (65,789 units at $1.52), increasing direct ownership by 263% to 90,789 units (SEC Form 4)

    4 - Unusual Machines, Inc. (0001956955) (Issuer)

    10/31/24 4:02:16 PM ET
    $UMAC
    Radio And Television Broadcasting And Communications Equipment
    Technology

    Director Rich Sanford bought $99,999 worth of shares (65,789 units at $1.52), increasing direct ownership by 124% to 118,696 units (SEC Form 4)

    4 - Unusual Machines, Inc. (0001956955) (Issuer)

    10/31/24 4:02:15 PM ET
    $UMAC
    Radio And Television Broadcasting And Communications Equipment
    Technology

    $ENLV
    $UMAC
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Maxim Group initiated coverage on Unusual Machines with a new price target

    Maxim Group initiated coverage of Unusual Machines with a rating of Buy and set a new price target of $18.00

    12/18/24 8:12:02 AM ET
    $UMAC
    Radio And Television Broadcasting And Communications Equipment
    Technology

    H.C. Wainwright reiterated coverage on Enlivex Therapeutics with a new price target

    H.C. Wainwright reiterated coverage of Enlivex Therapeutics with a rating of Buy and set a new price target of $33.00 from $22.00 previously

    3/2/21 6:56:26 AM ET
    $ENLV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ENLV
    $UMAC
    Leadership Updates

    Live Leadership Updates

    View All

    U.S. Defense Secretary Fast-Tracking Drone Production a Massive Win for Drone Stocks

    MarketNewsUpdates News Commentary NEW YORK, July 11, 2025 /PRNewswire/ -- On Thursday U.S. Defense Secretary Pete Hegseth announced breaking developments for the Drone Manufacturing Industry by issuing new orders to fast-track drone manufacturing operations, cutting red tape by calling for extensive reforms to Pentagon drone-buying practices.  Hegseth announced he was signing memos to rescind restrictive policies regarding drone production and deployment.  The memos state that the Defense Secretary plans to delegate authorities to procure and operate drones, deemed "vital" technology.  Shares of drone manufacturers jumped in the premarket today following yesterday's announcement.  The announ

    7/11/25 11:20:00 AM ET
    $KTOS
    $RCAT
    $UAVS
    Military/Government/Technical
    Industrials
    Computer Software: Prepackaged Software
    Technology

    Unusual Machines Appoints Brad Mello as VP of Manufacturing to Advance Domestic Production

    ORLANDO, FL / ACCESSWIRE / January 14, 2025 / Unusual Machines, a leading innovator in drone technology with a current focus on U.S. based manufacturing and marketing of drone parts, is excited to announce the appointment of Brad Mello as Vice President of Manufacturing. With an extensive background in automotive manufacturing, industrial automation, and consumer products, Brad is uniquely positioned to lead the development of Unusual Machines' drone components business, driving innovation and operational excellence.In his new role, Brad will initially focus on establishing in-house manufacturing capabilities for high-performance brushless motors, a key drone component. This initiative is a

    1/14/25 8:45:00 AM ET
    $UMAC
    Radio And Television Broadcasting And Communications Equipment
    Technology

    Unusual Machines to Host Q3 Earnings Call and Provide Corporate Update on Thursday, November 14, 2024

    ORLANDO, FL / ACCESSWIRE / November 8, 2024 / Unusual Machines, Inc. (NYSE:UMAC) (the "Company"), a leader in the American drone industry, will host a webcast on Thursday, November 14, at 4:30 p.m. ET to discuss the Company's operational and financial highlights for the third quarter ended September 30, 2024. A question-and-answer session will follow management's prepared remarks.Event:Unusual Machines Third Quarter 2024 Financial Results Conference CallDate:Thursday, November 14, 2024Time:4:30 p.m. Eastern TimeWebcast:Registration LinkFor interested individuals unable to join the live event, a webcast replay will be available for three months through the Investor Relations section of Unusua

    11/8/24 8:32:00 AM ET
    $UMAC
    Radio And Television Broadcasting And Communications Equipment
    Technology

    $ENLV
    $UMAC
    Financials

    Live finance-specific insights

    View All

    Enlivex Therapeutics and bioAffinity Technologies Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

    ORLANDO, FL / ACCESSWIRE / January 10, 2025 / RedChip Companies will air interviews with Enlivex Therapeutics Ltd. (NASDAQ:ENLV) and bioAffinity Technologies, Inc. (NASDAQ:BIAF) on the RedChip Small Stocks, Big Money™ show, a sponsored program on Bloomberg TV, this Saturday, January 11, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.Access the interviews in their entirety at:ENLV: https://www.redchip.com/assets/access/enlv_accessBIAF: https://www.redchip.com/assets/access/biaf_accessIn an exclusive interview, Oren Hershkovitz, CEO of Enlivex Therapeutics, appears on the RedChip Small Stocks Big Money™ show on Bloomberg TV to provide a c

    1/10/25 9:00:00 AM ET
    $BIAF
    $ENLV
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care
    Biotechnology: Pharmaceutical Preparations

    Enlivex Therapeutics and Biotricity Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

    ORLANDO, FL / ACCESSWIRE / July 19, 2024 / RedChip Companies will air interviews with Enlivex Therapeutics Ltd. (NASDAQ:ENLV) and Biotricity, Inc. (NASDAQ:BTCY) on the RedChip Small Stocks, Big Money™ show, a sponsored program on Bloomberg TV, this Saturday, July 20, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.Access the interviews in their entirety at:Enlivex Therapeutics: https://www.redchip.com/assets/access/enlv_accessBiotricity: https://www.redchip.com/assets/access/btcy_accessOren Hershkovitz, Ph.D., CEO of Enlivex Therapeutics, appears on the RedChip Small Stocks, Big Money™ show on Bloomberg TV to provide a corporate update.

    7/19/24 9:00:00 AM ET
    $BTCY
    $ENLV
    Medical/Dental Instruments
    Health Care
    Biotechnology: Pharmaceutical Preparations

    Calidi Biotherapeutics and Unusual Machines Interviews to Air on the RedChip Small Stocks, Big Mone(TM) Show on Bloomberg TV

    ORLANDO, FL / ACCESSWIRE / May 17, 2024 / RedChip Companies will air interviews with Calidi Biotherapeutics Inc. (NYSE:CLDI) and Unusual Machines Inc. (NYSE:UMAC) on the RedChip Small Stocks, Big Money™ show, a sponsored program on Bloomberg TV, this Saturday, May 18, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.Access the interviews in their entirety at:Calidi Biotherapeutics: https://www.redchip.com/assets/access/cldi_accessUnusual Machines: https://www.redchip.com/assets/access/umac_accessIn an exclusive interview, Allan Camaisa, Chief Executive Officer of Calidi Biotherapeutics, appears on the RedChip Small Stocks, Big Money™ show

    5/17/24 9:00:00 AM ET
    $CLDI
    $UMAC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Radio And Television Broadcasting And Communications Equipment
    Technology

    $ENLV
    $UMAC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Unusual Machines Inc.

    SC 13G/A - Unusual Machines, Inc. (0001956955) (Subject)

    11/14/24 4:29:47 PM ET
    $UMAC
    Radio And Television Broadcasting And Communications Equipment
    Technology

    SEC Form SC 13G filed by Enlivex Therapeutics Ltd.

    SC 13G - Enlivex Therapeutics Ltd. (0001596812) (Subject)

    11/14/24 3:29:35 PM ET
    $ENLV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Unusual Machines Inc.

    SC 13G - Unusual Machines, Inc. (0001956955) (Subject)

    8/1/24 3:26:45 PM ET
    $UMAC
    Radio And Television Broadcasting And Communications Equipment
    Technology